Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	European Network for Health Technology Assessment (EUnetHTA)	Bamlanivimab for the treatment of COVID-19
2021	NIHR Health Technology Assessment programme	Reducing bias in trials from reactions to measurement: the MERIT study including developmental work and expert workshop
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Influence of COVID-19 vaccines on surgical practice
2021	National Institute for Health and Care Excellence (NICE)	Secukinumab for treating non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 719
2021	European Network for Health Technology Assessment (EUnetHTA)	Baricitinib for the treatment of COVID-19
2021	Health Information and Quality Authority (HIQA)	Analysis of factors associated with outbreaks of SARS-CoV-2 in nursing homes in Ireland
2021	Institute for Clinical and Economic Review (ICER)	Tezepelumab for severe asthma
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Proposed delay for safe surgery after COVID-19
2021	National Institute for Health and Care Excellence (NICE)	Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma. NICE technology appraisal guidance 720
2021	European Network for Health Technology Assessment (EUnetHTA)	Molnupiravir for the treatment of COVID-19
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Training programming for healthcare professionals: How to support patients with chronic diseases to self-manage their health]
2021	Institute for Clinical and Economic Review (ICER)	Mavacamten for hypertrophic cardiomyopathy: effectiveness and value
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Telehealth in surgery: an umbrella review
2021	National Institute for Health and Care Excellence (NICE)	Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 721
2021	European Network for Health Technology Assessment (EUnetHTA)	High-dose vitamin D for the treatment of COVID-19
2021	Ontario Health	Stance-control knee–ankle–foot orthoses for people with knee instability: a health technology assessment
2021	Institute for Clinical and Economic Review (ICER)	Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value
2021	National Institute for Health and Care Excellence (NICE)	Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. NICE technology appraisal guidance 722
2021	European Network for Health Technology Assessment (EUnetHTA)	Mavrilimumab for the treatment of COVID-19
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Stool DNA testing for colorectal cancer (CRC) screening
2021	Institute for Clinical and Economic Review (ICER)	Observational real-world evidence update. Prophylaxis of hereditary angioedema with Takhzyro and C1 inhibitors: effectiveness and value
2021	National Institute for Health and Care Excellence (NICE)	Bimekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 723
2021	European Network for Health Technology Assessment (EUnetHTA)	Ivermectin for the treatment of COVID-19
2021	Institute of Health Economics (IHE)	Optimizing vascular risk reduction initiatives in Alberta: a clinical review and economic analysis
2021	Institute for Clinical and Economic Review (ICER)	JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer. NICE technology appraisal guidance 724
2021	European Network for Health Technology Assessment (EUnetHTA)	Aspirin for the treatment of COVID-19
2021	NIHR Health Technology Assessment programme	Non-invasive imaging software to assess the functional significance of coronary stenoses: a systematic review and economic evaluation
2021	Institute for Clinical and Economic Review (ICER)	Aducanumab for Alzheimer's disease: effectiveness and value
2021	National Institute for Health and Care Excellence (NICE)	Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 725
2021	NIHR Health Technology Assessment programme	The ACUTE (Ambulance CPAP: Use, Treatment effect and Economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
2021	Swiss Federal Office of Public Health (FOPH)	Corneal collagen crosslinking for the treatment of progressive keratoconus
2021	Institute for Clinical and Economic Review (ICER)	Anti b-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma
2021	National Institute for Health and Care Excellence (NICE)	Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 726
2021	Swiss Federal Office of Public Health (FOPH)	Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis
2021	Institute for Clinical and Economic Review (ICER)	Belimumab and voclosporin for lupus nephritis: effectiveness and value
2021	National Institute for Health and Care Excellence (NICE)	Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 727
2021	Institute for Clinical and Economic Review (ICER)	Treatments for anemia in chronic kidney disease: effectiveness and value
2021	National Institute for Health and Care Excellence (NICE)	Midostaurin for treating advanced systemic mastocytosis. NICE technology appraisal guidance 728
2021	Swiss Federal Office of Public Health (FOPH)	Medical cannabis for treating various symptoms in Switzerland
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Fall risk assessment in oncology patients
2021	Institute for Clinical and Economic Review (ICER)	Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Delaying surgery for patients recovering from COVID-19. A rapid review comissioned by RACS
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Phosphodiesterase type-5 inhibitors for the treatment of secondary Raynaud's phenomenon and digital ulcers
2021	National Institute for Health and Care Excellence (NICE)	Sapropterin for treating hyperphenylalaninaemia in phenylketonuria. NICE technology appraisal guidance 729
2021	Swiss Federal Office of Public Health (FOPH)	Palbociclib (Ibrance®), ribociclib (Kisqali®) and abemaciclib (Verzenios®) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative advanced breast cancer
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Effects of masks on the health of schoolchildren
2021	National Institute for Health and Care Excellence (NICE)	Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal). NICE technology appraisal guidance 730
2021	Ontario Health	Nonthermal endovenous treatments for varicose veins
2021	Swiss Federal Office of Public Health (FOPH)	Subacromial decompression as a primary/isolated intervention to treat subacromial pain
2021	NIHR Health Technology Assessment programme	Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
2021	National Institute for Health and Care Excellence (NICE)	Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal). NICE technology appraisal guidance 731
2021	Ontario Health	Prostatic artery embolization for benign prostatic hyperplasia
2021	Swiss Federal Office of Public Health (FOPH)	The treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines
2021	Belgian Health Care Knowledge Centre (KCE)	Long COVID: Pathophysiology – epidemiology and patient needs
2021	National Institute for Health and Care Excellence (NICE)	Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal). NICE technology appraisal guidance 732
2021	Ontario Health	Skin substitutes for adults with diabetic foot ulcers and venous leg ulcers
2021	National Institute for Health and Care Excellence (NICE)	Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 733
2021	Ontario Health	Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression
2021	National Institute for Health and Care Excellence (NICE)	Secukinumab for treating moderate to severe plaque psoriasis in children and young people. NICE technology appraisal guidance 734
2021	Ontario Health	Pigmented lesion assay for suspected melanoma lesions
2021	National Institute for Health and Care Excellence (NICE)	Tofacitinib for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 735
2021	Ontario Health	Proton Beam Therapy for Cancer in Children and Adults: A Health Technology Assessment
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. NICE technology appraisal guidance 736
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: mandatory vaccination
2021	Health Technology Wales (HTW)	Handheld single lead electrocardiogram devices to detect atrial fibrillation in older adults and those with intermittent episodes
2021	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer. NICE technology appraisal guidance 737
2021	Ontario Health	Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2021	Health Technology Wales (HTW)	Point-of-care ultrasound to diagnose gallstone disease
2021	National Institute for Health and Care Excellence (NICE)	Berotralstat for preventing recurrent attacks of hereditary angioedema. NICE technology appraisal guidance 738
2021	Ontario Health	Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2021	Scottish Medicines Consortium (SMC)	Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021	National Institute for Health and Care Excellence (NICE)	Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable. NICE technology appraisal guidance 739
2021	Scottish Medicines Consortium (SMC)	Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021	National Institute for Health and Care Excellence (NICE)	Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 740
2021	Scottish Medicines Consortium (SMC)	Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2021	Health Technology Wales (HTW)	Natriuretic peptides to rule-in and rule-out a diagnosis of acute heart failure in adults in the emergency department setting
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	National spending and uptake of mobile radiology services in aged care facilities: an opportunity to improve access remains
2021	National Institute for Health and Care Excellence (NICE)	Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 741
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Ambulatory antibiotic prophylaxis for skin procedures
2021	National Institute for Health and Care Excellence (NICE)	Selpercatinib for treating advanced thyroid cancer with RET alterations. NICE technology appraisal guidance 742
2020	Technology Assessment at SickKids (TASK)	Microcosting of whole genome sequencing (WGS) of trios in heterogeneous pediatric cardiac population
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: prophylactic use of hydroxychloroquine (HCQ)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: treatment with hydroxychloroquine (HCQ)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: infectivity of patients who have recovered from disease
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Cytokine adsorption for treatment of COVID-19 disease
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: decontamination and reprocessing of personal protective equipment (PPE)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Transmission of respiratory infections via showers
2020	NIHR Health Technology Assessment programme	Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Remdesivir for treatment of COVID-19 disease
2020	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Treatment of depression with transcranial magnetic stimulation using an H-coil (dTMS)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: sedation-ventilation liberation of COVID+ patients
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: surgical masks and filtering face piece respirators (FFR) for health care providers
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: point-of-care (POC) testing
2020	Adelaide Health Technology Assessment (AHTA)	Genetic testing for diagnosis of inheritable cardiac rhythm disorders
2020	NIHR Health Technology Assessment programme	Best-practice prevention alone or with conventional or biological caries management for 3- to 7-year-olds: the FiCTION three-arm RCT
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: antibiotic management in ambulatory patients
2020	Adelaide Health Technology Assessment (AHTA)	Detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibody (MOG) antibodies for diagnosis of neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein antibody-related demyelination (MARD)
2020	NIHR Health Technology Assessment programme	Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCT
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: temperature screening for healthcare personnel